Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20116116 | 1.00 | MAPT (0.51) | MAPTSMN1; SMN2PREPMAPK1ALDH1A1 | |
| SCHEMBL26998186 | 0.92 | MAPT (0.49) | MAPTSMN1; SMN2PREPMAPK1ALDH1A1 | |
| SCHEMBL20116114 | 0.86 | SMN1; SMN2 (0.52) | MAPTSMN1; SMN2PREPPOLBP2RY12 | |
| SCHEMBL30506331 | 0.83 | SMN1; SMN2 (0.50) | MAPTSMN1; SMN2PREPPOLBKMT2A | |
| SCHEMBL20116112 | 0.83 | SMN1; SMN2 (0.50) | MAPTSMN1; SMN2PREPPOLBKMT2A | |
| SCHEMBL22357815 | 0.83 | PREP (0.53) | MAPTSMN1; SMN2PREPPOLBP2RY12 | |
| SCHEMBL20116462 | 0.81 | SMO (0.57) | SMN1; SMN2MAPK1MEN1KMT2ALDHA | |
| SCHEMBL30720960 | 0.81 | SMO (0.57) | SMN1; SMN2MAPK1MEN1KMT2ALDHA | |
| SCHEMBL22358276 | 0.81 | MEN1 (0.53) | MAPTSMN1; SMN2MAPK1ALDH1A1HPGD | |
| SCHEMBL20116115 | 0.80 | LDHA (0.58) | MAPTSMN1; SMN2PREPMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| CN-110099898-B | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2023-07-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | MAPT 22/4885SMN1; SMN2 13/4885PREP 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.